Skip to main content
. 2019 Jan 29;10(4):821–828. doi: 10.7150/jca.27899

Table 3.

Associations between gene mutations and clinicpathological characteristics of patients.

KRAS P -value PIK3CA P -value BRAF P -value
Mutation Wild type Mutation Wild type Mutation Wild type
n (%) n (%) n (%) n (%) n (%) n (%)
Gender
Male 12 (60.0) 318 (68.4) 0.432 12 (66.7) 318 (68.1) 1.000 3 (50.0) 327 (68.3) 0.341
Female 8 (40.0) 147 (31.6) 6 (33.3) 149 (31.9) 3 (50.0) 152 (31.7)
Age, years
<45 2 (10.0) 57 (12.3) 0.933 4 (22.2) 55 (11.8) 0.332 1 (16.7) 58 (12.1) 0.572
45-49 2 (10.0) 40 (8.6) 1 (5.6) 41 (8.8) 0 42 (8.8)
50-70 13 (65.0) 276 (59.4) 10 (55.6) 279 (59.7) 5 (83.3) 284 (59.3)
≥70 3 (15.0) 92 (19.7) 3 (16.6) 92 (19.7) 0 95 (19.8)
TNM stage
I 1(5.0) 67 (14.4) 0.525 3 (16.7) 65 (13.9) 0.179 0 68 (14.2) 0.009
II 7 (35.0) 94 (20.2) 6 (33.3) 95 (20.3) 0 101 (21.1)
III 5 (25.0) 189 (40.6) 7 (38.9) 187 (40.0) 1 (16.7) 193 (40.3)
IV 7 (35.0) 115 (24.8 ) 2 (11.1) 120 (25.8) 5 (83.3) 117 (24.4)
Tumor location
Upper 7 ( 35.0) 140 (30.1) 0.646 5 (27.8) 142 (30.4) 0.634 3 (50.0) 144 (30.1) 0.937
Middle 6 (30.0) 85 (18.3) 6 (33.3) 85 (18.2) 0 91 (19.0)
Lower 3 (15.0) 198 (42.6) 6 (33.3) 195 (41.8) 1 (16.7) 200 (41.8)
Residual gastric or total gastric 4 (20.0) 42 (9.0) 1 (5.6) 45 (9.6) 2 (33.3) 44 (9.1)
Lymph node status
pN0 10 (50.0) 138 ( 29.7) 0.139 22.2(4) 144 (30.8) 0.556 0 148 (30.9) 0.320
pN1 5 (25.0) 132 ( 28.4) 38.9(7) 130 (27.8) 3 (50.0) 134 (28.0)
pN2 2 (10.0) 139 (29.9) 16.7(3) 138 (29.6) 2 (33.3) 139 (29.0)
pN3a/b 3 (15.0) 56 (12.0) 22.2(4) 55 (11.8) 1 (16.7) 58 (12.1)